NCT03906617

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Title of Project: Liposomal Bupivacaine (Exparel) Versus Bupivacaine And Dexamethasone Intercostal Nerve Blocks For Robotic Thoracic Surgery: A Prospective Randomized Single-Blinded Clinical Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: The Cooper Health System · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.

Conditions

• Robotic Lung Surgery

Interventions

Type	Name	Description
DRUG	Intercostal nerve block and wound infiltration with liposomal bupivacaine	Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
DRUG	Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone	Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.

Timeline

• Start date: 2019-04-10
• Primary completion: 2022-04-10
• Completion: 2022-06-10
• First posted: 2019-04-08
• Last updated: 2021-11-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study